Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
June 2023 in “Small animal advances” Selamectin spot-on effectively treats scabies in rabbits.
December 2023 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
March 2025 in “OncoTargets and Therapy” A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.
1 citations
,
August 2023 in “Journal of Dentomaxillofacial Science” Freeze-dried platelet-rich plasma boosts bone growth in gum treatment.
12 citations
,
December 2017 in “Scientific reports” The new test can measure very small amounts of testosterone in hair, and grinding the hair up first gives more accurate results.
21 citations
,
December 1994 in “Journal of Investigative Dermatology”
1 citations
,
January 1997 in “Journal of Investigative Dermatology” RU58841, an androgen receptor blocker, significantly increased hair density, thickness, and length in monkeys when applied topically daily for several months.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
53 citations
,
May 1996 in “The Journal of Clinical Endocrinology & Metabolism” Different mutations in the 5 alpha-reductase-2 gene were found in affected individuals in the Dominican Republic, suggesting no common ancestry.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
6 citations
,
February 2013 in “Medical Oncology” Certain genetic variants increase the risk of resistance to hormone therapy in prostate cancer patients.
August 2025 in “Pharmaceutics” A new method improves betulin delivery and shows promise in cancer treatment.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
May 2022 in “Reactions Weekly” The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
27 citations
,
November 2012 in “Journal of Biomedical Optics” Confocal Raman microscopy can effectively study drug delivery in hair follicles using pig ear models.
77 citations
,
January 1980 in “Carcinogenesis” TPA is about 50 times more effective at promoting tumors than MZ.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
53 citations
,
October 2011 in “Psychoneuroendocrinology” Finasteride may help improve certain brain function issues linked to dopamine.
9 citations
,
August 2020 in “Ecological indicators” Laser ablation ICP-MS is effective for tracking trace elements in polar bear hair over time.
4 citations
,
February 2024 in “The Journal of Urology” Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.
March 2026 in “Journal of Enzyme Inhibition and Medicinal Chemistry” PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.
1 citations
,
September 2022 in “Sudan Journal of Medical Sciences” Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.
82 citations
,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.